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Abstract
Background. Patients with chronic kidney disease (CKD) have increased all-cause mortality, especially cardiovascu-
lar. The majority of patients with CKD have stages 1–3 and are treated by primary care physicians and nephrologists. 
Arterial hypertension (HTN) is highly prevalent comorbidity among CKD population, but its control remains poor. 
Material and methods. This retrospective non-interventional cross-sectional study was conducted in the Centre of 
Nephrology Care in Dnipropetrovsk Mechnikov Regional Hospital, Dnipro, Ukraine. We aimed to select patients 
who are supposed to be followed-up by primary care practitioners but due to certain reasons required nephrologist’s 
consultation. From 4540 patients who received medical care in the Centre of Nephrology Care 365 patients fulfilled 
inclusion criteria. They were subdivided by presence of HTN, CKD stage, presence of proteinuria and achieving 
blood pressure targets according to different standards. All patients were examined and followed-up according to 
local and European standards. 
Results. Forty-nine percent of patients had known HTN, and 21% had HTN de novo. Advance of CKD stage was 
significantly associated with increase in the most of laboratory findings, age and BP values. Non-proteinuric patients 
achieved BP goals significantly more often, than proteinuric ones. Females achieved BP targets more often, than 
males. Monotherapy was the most common treatment regimen. 
Conclusions. HTN occurs in 70% of patients with CKD and it is controlled in up to 34% of cases. HTN is im-
portant factor of CKD progression and it is closely connected with GFR and proteinuria.
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Introduction
Patients with chronic kidney disease (CKD) have in-
creased risk of mortality, cardiovascular (CV) disease 
and development of end-stage renal disease (ESRD) 
[1]. The majority of patients with CKD have stag-
es 1–3 and are treated by primary care physicians 
(PCPs) and nephrologists [2]. Management of pa-
tients with early-stages CKD is problematic, because 
there is no sufficient evidence on the expediency of 
early CKD intervention [2].
Arterial hypertension (HTN) is highly prevalent 
in CKD population [3] and it is the second cause 
of end-stage renal disease worldwide [4]. Control 
of HTN in CKD patients remains suboptimal 
regardless of region and it may be due to vari-
ous reasons: poorly controlled HTN in advanced 
stages of CKD, low awareness of HTN treatment 
guidelines in CKD patients, inadequate drug or 
dose choice etc. [2]. Importantly, CKD patients 
are older than in general population [5] and may 
require different blood pressure (BP) targets [6]. 
In elderly individuals, age-related decline in glo-
merular filtration rate (GFR) may be difficult to 
differentiate from CKD [7].
But for the majority of patients with CKD it is 
still uncertain what BP targets should be chosen 
and what should be taken into consideration be-
fore choosing BP target. BP management guide-
lines, provided by International Society of Nephrol-
ogy (KDIGO) [8], European Society of Cardiol-
ogy (ESC) [9] and American College of Cardiology 
(ACC) [10] and issued between 2012th and 2017th 
tended to get stricter with time and 2017 ACC 
guidelines recommend target BP for patients with 
CKD to be < 130/80 mm Hg. But despite convinc-
ing results of SPRINT trial [11], showing benefits of 
strict BP control in patients with CKD, Hyperten-
sion Canada’s 2018 Guidelines for Diagnosis, Risk 
Assessment, Prevention, and Treatment of Hyper-
tension in Adults and Children [12] changed BP 
goals for patients with CKD to < 140/90 mm Hg, 
leaving BP target < 130/80 mm Hg for patients with 
diabetes mellitus (DM). 
Results of SPRINT trial may be difficult to ex-
trapolate to general CKD population due to exclu-
sion from the trial patients with DM and heart 
failure and due to the method of BP measurement, 
showing BP values from 5 to 20 mmHg lower, 
than could be obtained using routine methods [5]. 
At the same time data about inverse relationship 
of BP and patients’ negative clinical outcomes are 
accumulating. Concept of so-called J curve was 
emerged and confirmed by several researchers and 
inverse association with BP was fair only for all-
cause mortality, but not for incidence of coronary 
heart disease, ischaemic stroke or ESRD [5]. No-
tably, adverse impact of low BP values on the risk 
of CV death was more prominent, than the impact 
of high BP [5].
The aim of this study is to assess BP control in 
patients with non-dialysis CKD referred by PCPs to 
the Centre of Nephrology Care.
Material and methods 
This retrospective non-interventional cross-sectional 
study was conducted in the Centre of Nephrology 
Care in Dnipropetrovsk Mechnikov Regional Hos-
pital, Dnipro, Ukraine. We aimed to select patients 
who are supposed to be followed-up by primary care 
practitioner (PCP), but which due to certain reasons 
required nephrologist’s consultation. Overall 4540 
patients received medical care in Centre of Nephrol-
ogy Care in Dnipropetrovsk Mechnikov Regional 
Hospital during 2017. We excluded patients with 
type 1 DM, polycystic renal disease, hereditary re-
nal diseases, operations on kidneys or urinary tract 
(n  =  874) because they require multidisciplinary 
medical approach and are not treated by PCPs. 
We also excluded patients with GFR < 30 ml/min 
(n = 351) as also requiring cooperation of nephrolo-
gist with other specialists due to CKD complications 
and preparing patients to renal replacement therapy. 
On the next step independent expert excluded 2950 
patients as those that had no CKD or didn’t require 
re-examination and could be followed-up in primary 
care. Thus, into the study were enrolled 365 patients 
with CKD that were followed-up in primary care, 
but required re-examination (including assessment 
of proteinuria, GFR and BP control) or revision 
of the treatment. All patients were examined and 
followed-up according to local and European stan-
dards and gave informed written consent on data 
collection. The study was approved by the Ethics 
Committee at the Dnipropetrovsk Mechnikov Re-
gional Hospital, Dnipro, Ukraine. Study design is 
shown on Figure 1.
BP control was assessed according to following 
standards: KDIGO Clinical Practice Guideline 
for the Management of Blood Pressure in Chron-
ic Kidney Disease [8] (BP goal ≤ 140/90 mm Hg 
or ≤  130/80 mm Hg < if albumin excretion rate 
(AER) > 30 mg/24 hours); 2013 ESH/ECS Guide-
line for management of HTN [9] (BP goal — sys-
tolic BP (SBP) < 140 mm Hg); 2016 European 
guidelines on CV disease prevention in clinical prac-
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tice [13] (BP goal < 140/90 mm Hg); 2017 ACC/
AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA Guideline for the Prevention, Detec-
tion, Evaluation, and Management of High Blood 
Pressure in Adults [10] (BP goal < 130/80 mm Hg) 
and Hypertension Canada’s 2018 Guidelines for 
Diagnosis, Risk Assessment, Prevention, and Treat-
ment of Hypertension in Adults and Children [12] 
(BP  goal < 140/90 mm Hg or < 130/80 mm Hg 
for patients with DM). HTN was diagnosed in case 
of previously existing diagnosis of HTN or SBP 
≥ 140 mm Hg or DBP ≥ 90 mm Hg at the moment 
of admission to the Centre of Nephrology Care. At 
the moment of data collection patients with known 
HTN were already prescribed antihypertensive treat-
ment. In order to examine the effectiveness of treat-
ment regimens (count and classes of drugs) we com-
pared these patients to those, who achieved BP goals 
according to different standards.
Anaemia was diagnosed if haemoglobin was 
< 120 g/L in females and < 130 g/L in males. Left 
ventricular hypertrophy (LVH) was diagnosed us-
ing Sokolow-Lyon index after 12-lead electrocardi-
ography. Proteinuria was diagnosed if urine albumin 
excretion was > 0.03 g/L or protein trace was found 
in morning urine void. Risk of CKD progression was 
assessed according to KDIGO 2012 Clinical Practice 
Guideline for the Evaluation and Management of 
Chronic Kidney Disease [14]. In purpose to classify 
patients to albuminuria categories we used albumin 
excretion rate (AER). Body mass index (BMI) was 
estimated as weight (kg)/[height (m)]2. GFR was 
calculated using GFR-EPI equation [14].
Statistical analysis
Due to skewness of the data distribution, values 
were presented as median and interquartile range 
(IQR). Categorical data are presented as n (valid %) 
to avoid confounding true proportion by missing 
data. Mann-Whitney and Kruskal-Wallis test were 
used to compare continuous data, c2 test was used 
for comparing categorical data. Non-parametric 
Spearman’s correlation coefficient (r) was used. In 
most cases critical value of p was < 0.05. In cases of 
multiple comparisons we used Bonferroni correction 
and critical value of p equalled to 0.05/(number of 
possible comparisons). Data analysis was performed 
using Libre Office and R.
Patients reffered to the Center of Nephrology
Care by PCPs in 2017
(n = 4540)
Patients with T1DM, congenital anomalies
of the kidney and the urinary tract, renal stone
disease, polycystic kidney disease, 
acute kidney injury (n = 874)
Patients with stage 4–5 CKD (n = 351)
Patients that didn’t require reexamination
and could be followed up in primary care
(n = 2950)
Patients that are supposed 
to be treated by PCP
(n = 3315)
Patients that required reexamination
or revision of treatment
(n = 365)
Subanalysis 
by presence of AH
—
Known AH (n = 178)
AH onset (n = 77)
Normotensive (n = 110)
Subanalysis 
by CKD stage
—
CKD 1 (n = 137)
CKD 2 (n = 111)
CKD 3 (n = 117)
Subanalysis 
by presence of proteinuria
—
Proteinuria (n = 170)
No proteinuria (n = 173)
Subanalysis 
by achieved BP goals
—
KDIGO 2012 (n = 58)
ESC 2013 (n = 54)
ESC 2016 (n = 44)
ESC 2017 (n = 11)
ESC 2018 (n = 37)
Figure 1. Study design. PCPs — primary care physicians; T1DM — type 1 diabetes mellitus; CKD — chronic kidney disease; HTN — arterial 
hypertension; KDIGO — Kidney Disease Improving Global Outcomes; ESC — European Society of Cardiology; ACC — American College of 
Cardiology; CCS — Canadian Cardiovascular Society
Olexandr Kuryata et al. Hypertension in chronic kidney disease
91www.ah.viamedica.pl
Results 
Majority of patients were females, but in group of 
patients with HTN de novo males predominated. 
Nearly 70% of patients had known HTN or HTN 
de novo. Median age differed significantly with dis-
tance of more than 10 years, being the highest in 
patients with known HTN. BMI, as well as age, was 
higher in hypertensive patients, especially in those 
with known HTN. DM, LVH and proteinuria were 
revealed more often in hypertensive patients, while 
anaemia (non-significantly) — in normotensive 
ones. Patients with HTN also had higher cholesterol 
levels and lower GFR, but there was no significant 
difference in CKD duration between groups. Nor-
motensive patients had normal median GFR, while 
in hypertensive patients renal function was mildly or 
moderately decreased. Hypertensive patients contrib-
uted mainly to high risk groups of CKD progression. 
Clinical characteristics of patients in the study 
are shown in the Table I. Clinical characteristics of 
patients with preserved renal function depending on 
presence of proteinuria are presented in the Table II. 
Information about treatment regimens of patients, 
who achieved BP control according to different 
standards and patients’ characteristics are shown in 
Table III.
Prevalence of comorbid conditions increased as 
GFR declined (Fig. 2). Distribution of patients with 
low, moderately high, high and very high risk of CKD 
progression was the following: patients with stage 1 
CKD — 66%, 23%, 1%, 0%; patients with stage 2 
CKD — 69%, 19%, 12%, 0%; patients with stage 
3 CKD — 0%, 29.8%, 35.1%, 35.1%. Decline in 
GFR was significantly associated with rise of median 
age (r = –0.56), SBP (r = –0.38), DBP (r = –0.28), 
BMI (r = –0.41), serum uric acid (r =  –0.44), HTN 
duration (r = –0.36; p < 0.001 for all correlations) 
and with AER (r = –0.14; p = 0.019).
Patients with proteinuria had higher prevalence of 
DM and HTN and more often suffered from anae-
mia and LVH (Tab. II). In both groups patients had 
Table I. Clinical characteristics of patients in the study
Parameter
Total Known HTN HTN de novo Normotensive
N (valid %)
Total 365 (100.0) 178 (48.8) 77 (21.0) 110 (30.1)
Malea, c 155 (42.5) 68 (38.2) 44 (57.1) 43 (39.1)
Femalea, c 210 (57.5) 110 (61.8) 33 (42.9) 67 (60.9)
DMb 61 (16.7) 48 (27.0) 12 (15.6) 1 (0.9)
Anaemia 103 (28.2) 50 (28.1) 14 (18.1) 39 (35.5)
LVHb, c 77 (21.1) 62 (34.8) 14 (18.2) 1 (0.9)
Proteinuriab, c 170 (49.6) 90 (52.9) 42 (58.3) 38 (37.6)
Risk of 
CKD pro-
gression
Low 125 (45.0) 51 (34.9) 27 (46.6) 47 (63.5)
Moderately high 66 (23.7) 39 (26.7) 11 (19.0) 16 (21.6)
High 54 (19.4) 31 (21.2) 14 (24.1) 9 (12.2)
Very high 33 (11.9) 25 (17.1) 6 (10.3) 2 (2.7)
Median [IQR]
Age (years)a, b, c 44 [29.5;60] 57 [44.7;66] 40 [31;53] 29.5 [24;38.2]
BMI [kg/m2] a, b, c 26.1 [22.2;30.8] 29.3 [25.6;32.1] 26 [22.7;30.8] 21.6 [19.6;24.6]
CKD duration (years) 5 [1;15.7] 6 [2;15.5] 8 [2;19.5] 4 [1;12]
HTN duration (years) a, b, c 0 [0;8] 5.5 [0;13] 0 [0;0] 0 [0;0]
SBP [mm Hg]a, b, c 130 [120;150] 140 [130;160] 135 [122.5;150] 110 [100;120]
DBP [mm Hg]b, c 85 [75;95] 90 [80;100] 90 [80;95] 70 [70;80]
GFR [mL/min]a, b, c 79.3 [51.5;101.6] 60.5 [44.5;86.6] 80.7 [58.0;99.2] 102.2 [80.5;117.9]
Uric acid [mmol/L] 391 [318;483] 395 [314;483] 369.5 [321;466] 411 [316;507]
Total cholesterol [mmol/L] 5.2 [4.4;5.9] 5.2 [4.5;5.8] 5.7 [4.5;6.6] 4.9 [3.8;6.4]
AER [mg/24 h] 0 [0;72] 0 [0;72] 0 [0;117] 0 [0;51]
HTN — arterial hypertension; CKD — chronic kidney disease; DM — diabetes mellitus; LVH — left ventricle hypertrophy; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure;  
GFR — glomerular filtration rate; AER — albumin excretion rate; a“Known HTN” vs. “HTN de novo”; b“Known HTN” vs. “Normotensive”; c“HTN de novo” and “Normotensive”, p < 0.016 for all comparisons
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comparable age and duration of CKD and HTN, but 
proteinuric patients had more severe course of HTN, 
assessed by grade of HTN. Non-proteinuric patients 
achieved BP goals significantly more often, then those 
with proteinuria. Percentage of prescription antipro-
teinuric drugs such as angiotensin converting enzyme 
inhibitors (ACEI) and angiotensin receptor blockers 
(ARB) was 15.3% and 21.2%. 
Females achieved BP targets more often than 
males and in ACC 2017 group females’ proportion 
was the highest (Tab. III). The lowest frequency of 
DM was in CCS 2018 group, the highest — in ACC 
2017 group. We observed in all treated hypertensive 
patients, as compared to patients with controlled 
BP, higher frequency of LVH, proteinuria, higher 
median BMI, uric acid and lower median GFR. 
Prevalence of LVH and proteinuria was relatively low 
in ACC 2017 and KDIGO 2012 groups. Classes of 
antihypertensive drugs are ordered in frequency of 
usage. The most widely used classes were renin-an-
Table II. Clinical characteristics of patients depending on presence of proteinuria
Parameter
With proteinuria Without proteinuria P value
N (valid %)
Total 170 (49.5) 173 (50.5)
Males 71 (41.8) 77 (45.5) 0.60
Females 99 (58.2) 96 (55.5) 0.60
DM 33 (19.4) 26 (15.0) 0.28
Anaemia 63 (37.1) 33 (19.1) < 0.001
LVH 43 (25.3) 33 (19.9) 0.06
HTN 132 (77.6) 110 (63.6) 0.004
Controlled HTN according 
to guidelines
KDIGO 2012 56 (32.9) 26 (72.8) < 0.001
ESC 2013 78 (45.9) 112 (64.7) 0.02
ESC 2016 63 (37.1) 99 (52.7) 0.014
ACC 2017 30 (17.6) 52 (30.1) 0.15
CCS 2018 59 (34.7) 92 (53.2) 0.045
ESC grades of BP
Normal 25 (18.9) 36 (32.7)
Grade 1 HTN 53 (40.2) 49 (44.5)
Grade 2 HTN 36 (27.3) 18 (16.4)
Grade 3 HTN 18 (13.6) 7 (6.4)
Class of drug
ACEI 26 (15.3) 32 (18.5) 0.42
ARB 36 (21.2) 28 (16.2) 0.23
Diuretics 23 (13.5) 15 (8.7) 0.15
Beta-blockers 41 (24.1) 24 (13.9) 0.015
CCB 24 (14.1) 9 (5.2) 0.005
Median [IQR]
Age (years) 45 [31;59] 45 [28.5;61] 0.89
BMI [kg/m2] 26.4 [22.6;30.8] 26.0 [22.0;30.8] 0.58
CKD duration (years) 5 [2;13.2] 6 [1;16.7] 0.58
HTN duration (years) 0 [0;6.5] 0 [0;9] 0.89
SBP [mm Hg] 140 [120;150] 130 [110;140] < 0.001
DBP [mm Hg] 90 [80;100] 80 [75;90] 0.001
GFR [mL/min] 68.1 [45.6;99.4] 85.4 [62.2;106.4] < 0.001
Uric acid [mmol/L] 414 [328;502] 360 [302;440] 0.056
Total cholesterol [mmol/L] 5.5 [4.8;6.2] 5.1 [4.2;5.7] 0.13
DM — diabetes mellitus; LVH — left ventricle hypertrophy; HTN — arterial hypertension; KDIGO — Kidney Disease Improving Global Outcomes; ESC — European Society of Cardiology; ACC — American College of Car-
diology; CCS — Canadian Cardiovascular Society; ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blockers; CCB — calcium channel blockers; BMI — body mass index; CKD — chronic 
kidney disease; SBP — systolic blood pressure; DBP — diastolic blood pressure; GFR — glomerular filtration rate
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giotensin-aldosterone system blockers, and calcium 
channel blockers were used in the minority of cases. 
The most common mode of HTN treatment was 
monotherapy. In patients with controlled HTN, di-
uretics were used more commonly than in the whole 
cohort of patients receiving HTN treatment. The 
majority of patients with controlled HTN had low 
risk of CKD progression, regardless of chosen BP 
goals. Continuous values were roughly equal in all 
groups, but cholesterol level and GFR were slightly 
better in ACC 2017 group.
Discussion
Our study confirmed that HTN is highly prevalent 
among patients with CKD in ambulatory practice. 
The most optimal laboratory results and the lowest 
median age were observed in normotensive patients. 
This group also showed the highest proportion of 
low-risk patients for CKD progression. Slightly bet-
ter clinical characteristics of patients with HTN de 
novo as compared to patients with known HTN may 
be explained by age differences (more than 15 years) 
and milder course of hypertension (assessed by BP 
Table III. Clinical characteristics of patients who achieved BP control according to different standards
Parameter
HTN treatment guidelines
Known HTN KDIGO 2012 ESC 2013 ESC 2016 ACC 2017 CCS 2018
N (valid %)
Total 178 (100.0) 58 (34.1) 54 (30.3) 44 (24.7) 11 (6.2) 37 (20.8)
Males 68 (38.2) 18 (31.0) 19 (35.2) 16 (36.4) 2 (18.2) 12 (32.4)
Females 110 (61.8) 40 (69.0) 35 (64.8) 28 (63.6) 9 (81.8) 25 (67.6)
DM 48 (27.0) 13 (22.4) 13 (24.1) 10 (22.7) 3 (27.3) 3 (8.1)
Anaemia 50 (28.1) 13 (22.4) 12 (22.2) 11 (25.0) 4 (36.4) 9 (24.3)
LVH 62 (43.1) 13 (29.5) 16 (38.1) 14 (42.4) 2 (28.6) 9 (33.3)
Proteinuria 90 (52.9) 11 (19.0) 19 (36.5) 16 (38.1) 2 (20.0) 13 (37.1)
Class 
of drug
ACEI 56 (31.5) 19 (32.8) 20 (37.0) 15 (34.1) 4 (36.4) 13 (35.1)
ARB 66 (37.1) 22 (37.9) 19 (35.2) 17 (38.6) 3 (27.3) 14 (37.8)
Beta-blockers 66 (37.1) 14 (24.1) 12 (22.2) 11 (25.0) 4 (36.4) 8 (21.6)
Diuretics 37 (20.8) 14 (24.1) 13 (24.1) 12 (27.3) 4 (36.4) 9 (24.3)
CCB 36 (20.2) 6 (10.3) 6 (11.1) 5 (11.4) 1 (9.1) 4 (10.8)
Number 
of drugs
1 113 (63.5) 44 (75.9) 43 (79.6) 33 (75.0) 7 (63.6) 28 (75.7)
2 48 (27.0) 12 (20.7) 7 (13.0) 7 (15.9) 3 (27.3) 7 (18.9)
3 16 (9.0) 1 (1.7) 3 (5.6) 3 (6.8) 1 (9.1) 2 (5.4)
4 1 (0.6) 1 (1.7) 1 (1.9) 1 (2.3) 0 (0.0) 0 (0.0)
Risk of CKD 
progression
Low 51 (34.9) 21 (41.2) 21 (44.7) 14 (37.8) 5 (55.6) 11 (36.7)
Moderate 39 (26.7) 14 (27.5) 10 (21.3) 7 (18.9) 0 (0.0) 6 (20.0)
High 31 (21.2) 13 (25.5) 13 (27.7) 13 (35.1) 3 (33.3) 10 (33.3)
Very high 25 (17.1) 3 (5.9) 3 (6.4) 3 (8.1) 1 (11.1) 3 (10.0)
Median [IQR]
Age (years) 57 [44.7;66] 60 [43.7;65.2] 57.5 [42.2;65.2] 58.5 [40.7;66] 58 [40;63] 52 [36.5;64.5]
BMI [kg/m2] 29.3 [25.6;32.1] 28.3 [24.4;31.7] 27.2 [23.7;30.8] 27.0 [22.5;30.8] 27.0 [23.7;31.2] 26.7 [22.3;30.2]
CKD duration (years) 6 [2;15.5] 10 [2.5;14] 6 [2;12.2] 6 [2;12.7] 11 [4;22] 6 [2.5;13]
HTN duration (years) 5.5 [0;13] 4 [0;14] 5 [0;16] 4 [0;15.5] 6 [0;16] 4 [0;13.5]
GFR [mL/min] 60.5 [44.5;86.6] 67.0 [48.4;91.8] 74.3 [48.1;92.1] 70.5 [43.4;91.5] 74.2 [41.3;92.5] 72.9 [44.8;94.7]
Uric acid [mmol/L] 395 [314;483] 369.5 [296;416] 369.5 [304;464] 379 [302;483] 379 [251;446] 357 [297;407]
Total cholesterol [mmol/L] 5.2 [4.5;5.8] 5.5 [4.5;6.0] 5.4 [4.7;5.9] 5.4 [4.7;5.9] 4.0 [2.9;–] 5.6 [4.6;6.1]
AER [g/24 h] 0 [0;72] 0 [0;0] 0 [0;51] 0 [0;63] 0 [0;22] 0 [0;61]
HTN — arterial hypertension; ESC — European Society of Cardiology; KDIGO — Kidney Disease Improving Global Outcomes; ACC — American College of Cardiology; CCS — Canadian Cardiovascular Society;  
DM — diabetes mellitus; LVH — left ventricle hypertrophy; ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blockers; CCB — calcium channel blockers; BMI — body mass index;  
CKD — chronic kidney disease; SBP — systolic blood pressure; DBP — diastolic blood pressure; GFR — glomerular filtration rate; AER — albumin excretion rate
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levels and percentage of controlled BP). Nearly 50% 
of patients had proteinuria, and this proportion was 
even higher in hypertensive patients, while it should 
not exceed 40% according to Bolignano (2017) [4]. 
Forty-three percent of patients with known HTN 
had LVH, but even higher prevalence of LVH in 
hypertensive patients in Ukraine was given by Ragot 
[15]. This data indicate that HTN in Ukrainian 
patients, and in patients with CKD as well, is di-
agnosed with delay and BP control is not optimal. 
Hypertensive patients had higher risk of CKD pro-
gression and had significantly different GFR values, 
but not AER. We assume that in our cohort, the risk 
of CKD progression was in higher degree influenced 
by renal function loss.
Secondly, patients in our study differed from pop-
ulations reported in other studies in several ways. 
Overall females’ proportion in our study was slightly 
higher (Tab. I), while in meta-analysis of Mahmoodi 
et al. (2017) males were more prevalent in CKD 
populations [1]. At the same time, males predomi-
nated among patients with HTN de novo. Median 
age of males and females in our study was 37 (24; 50) 
years and 52.5 (33; 63) years, respectively (Fig. 3). 
The fact that males in our study were younger, than 
females may be explained by elevated alertness con-
cerning evaluation of CV diseases in Ukrainian men. 
According to ESC: Cardiovascular Disease Statistics 
2017 Ukrainian population (especially males) is at 
extremely high risk of mortality from CV disease 
complications [16]. Prevalence of DM among hy-
pertensive patients was much higher, than in other 
groups (Tab. I), and than in official statistics [16, 17]. 
Prevalence of DM among general Ukrainian popula-
tion is less than 3–4% [16, 17], but nearly 18% in 
patients with hypertension [15]. According to the 
data from National Registry of patients with CKD 
(2016) prevalence of diabetic nephropathy among 
patients with CKD was 24% for Ukraine and 23.2% 
for Dnipropetrovsk region. But patients with type 2 
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Figure 2. Prevalence of comorbidities depending on CKD stage. GFR — glomerular filtration rate; DM — diabetes mellitus; LVH — left ven-
tricle hypertrophy; HTN — arterial hypertension
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DM (which were included to our study) contributed 
only to 9.2% and 2.8% of patients for Ukraine and 
Dnipropetrovsk region respectively [18]. 
Next, we have found close interrelations be-
tween HTN, loss of renal function and protein-
uria. Patients in our study showed deterioration 
of laboratory and instrumental findings and 
raise of comorbidity along with advance of CKD 
stage (Fig. 2) and these findings do not contra-
dict existing concept of CKD progression [3]. In 
other study of Ukrainian patients with stage 4–5 
CKD normal BP was observed only in 10% of 
patients, LVH — in 90% and more than half 
of patients had BMI more than 30 kg/m2 [19]. 
Interestingly, decline of renal function is associ-
ated more strongly with CV risk factors than with 
AER. Severity of renal function loss is significantly 
associated with duration of HTN, but not du-
ration of CKD, and hypertensive patients seem 
to be that phenotype of CKD patients, prone to 
CKD progression. On average, proteinuric pa-
tients had preserved renal function (GFR > 60 ml/ 
/min) and more than 75% of proteinuric patients 
had HTN (Tab. II). Non-proteinuric patients had 
the same age, duration of CKD and HTN and gen-
der composition, but they had ~15% significantly 
lower prevalence of HTN and significantly higher 
median GFR. Non-proteinuric patients had higher 
frequency of controlled BP. These data point out 
strong association of HTN, proteinuria and renal 
function loss and partially correspond with Bolig-
nano’s review [4]: we agree that HTN is responsible 
for GFR lowering, but we find no data that absence 
of proteinuria elevates risk of CKD progression. 
According to CKD-ROUTE study patients with 
normal-range proteinuria are not in higher risk of 
renal function loss as compared to non-proteinuric 
patients [20]. 
And, finally, there are several findings concerning 
antihypertensive treatment and achieving BP targets. 
Proportions of drug types in all treated patients and 
in patients who achieved BP targets were roughly 
equal (Tab. III). Beta-blockers were used slightly 
more often in controlled patients while these drugs 
are supposed to be used in specific comorbidities 
(heart failure, coronary artery disease, atrial fibrilla-
tion etc. [8, 21]). CCB, that should be included into 
initial combination of antihypertensive drugs were 
used scarcely. The same pattern as in proportion of 
types of drugs was observed in number of used drugs. 
First of all, it may indicate on inadequate choice of 
dosage. The most common regimen was monothera-
py (60–80%), even higher in well-controlled patients 
(Tab. III), while guidelines state, that CKD patients 
usually require combination of antihypertensive 
drugs [8–10, 12, 13, 21]. Overall effectiveness of 
monotherapy in our study did not exceed 25% and 
we suggest that wider usage of combined therapy will 
allow reaching BP targets in higher percent of pa-
tients. Important question is whether it should start 
from combination, or drugs should be added in step-
wise manner, because it may influence frequency of 
drug-related side-effects as well as symptoms related 
to hypotension [22, 23]. 
Females achieved BP goals more often, regardless 
of chosen standard, which may be related to higher 
adherence to antihypertensive treatment [24]. Pa-
tients who achieved BP goals had the similar age, 
BMI, CKD and HTN duration, and DM preva-
lence as the whole cohort of hypertensive patients. 
Although overall proportion of controlled BP was 
low (34% and less), it wasn’t much lower, than in 
reported data [2]. Worth mentioning is the fact that 
approximately 70% of our patients received ACEI of 
ARB and it is rather similar to reports form primary 
care practitioners in USA [2], but low percentage of 
renin-angiotensin-aldosterone blockers in patients 
with proteinuria (Tab. II) is troublesome. Notable, 
diuretics, that were used scarcely showed good effec-
tiveness and their usage was more often in patients 
with controlled BP.
It is evident that achieving BP goals is beneficial, 
as patients with controlled HTN had better labora-
tory and instrumental findings (except of anaemia 
in ACC 2017 group). But it is still questionable 
whether achieving BP control allows improvement 
of patients’ characteristics, and, thus, their estimated 
risks, or such a low intensity of antihypertensive 
treatment allows achieving BP goals only in relatively 
healthy subjects. 
Patients who achieved BP levels of < 130/80 mm Hg 
are prominent in following aspects: 
• they had the most favourable laboratory param-
eters and low rates of LVH and proteinuria (albeit 
they had higher proportion of anaemia and DM); 
• usage of beta-blockers and diuretics in this group 
of patients was the most common;
• antihypertensive therapy in this group was the 
most intensive; 
• this group had the highest proportion of patients 
with low risk of CKD progression. 
Non-beneficial, as compared with other groups 
age and duration of HTN and CKD allow us to 
suggest that these patients were in the same condi-
tions with others. Kovesdy (2017) finds doubtful ex-
trapolation of SPRINT trial results on general CKD 
population, mainly due to exclusion of patients with 
DM and heart failure from the trial [5]. Taking into 
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account that 30% of patients in the group of strict 
control had DM, it is possible that achieving lower 
BP goals will result in better CV and CKD deteriora-
tion prognosis. But here we should also mention that 
usage of threshold of 130/80 mmHg for diagnosis 
of HTN reclassified 34% of normotensive patients 
with CKD in our study as hypertensive ones. Label-
ling individual as having disease may per se lead to 
perception of poor health and elevating of BP values 
through different mechanisms [6].
Conclusions
Arterial hypertension occurs in 70% of patients with 
CKD and it is controlled in up to 34% cases. Usage 
of ACC 2017 blood pressure targets reclassifies 34% 
of normotensive patients as hypertensive.  
Arterial hypertension is important factor of CKD 
progression and it is closely connected with GFR and 
proteinuria. Treatment of proteinuria is crucial in 
achieving BP goals in patients with CKD. 
Perspectives
ESC/ESH 2018 guidelines for the management of 
AH (21) recommend BB to be used in young fe-
males or in patients with specific conditions (such 
as heart failure, atrial fibrillation, coronary artery 
disease etc.). Patients in our study poorly fit these 
criteria, but in 1/3 of patients BB were used. Influ-
ence of BB on proteinuria and CKD progression is 
to be clarified.
According to our data patients with CKD stage 
2 have similar risk of CKD progression but higher 
CV risks than patients with CKD stage 1. Differ-
ences of CV and CKD progression risks in patients 
with CKD stages 1 and 2 are to be proven on larger 
patients cohorts. 
Limitations
Patients in our study were referred to our centre by 
primary care practitioners because of new symptoms 
or deterioration and, thus, they do not correspond 
totally with patients with early CKD in ambulatory 
practice. The fact that 21% of patients in our study 
had HTN de novo confirms this idea.
Gender aspects of CKD progression. In our study 
males and females had age difference of ~15 years that 
determines difficulties in comparing these groups. 
Effects of combinations of first-line antihyperten-
sive drugs weren’t investigated.
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